Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

Inflammatory Bowel Diseases Clinical Trial

Official title:

Serum NGAL as a Predictor of Clinical and Endoscopic Activity of Inflammatory Bowel Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05151458
• Other study ID #: NGAL in IBD
• Status: Not yet recruiting
• Start date: December 29, 2021
• Est. completion date: November 30, 2022

Study information

• Verified date: December 2021
• Source: Assiut University
• Contact: Mohamed Alsadek Ma Ghozaly, Master
• Phone: 01150993206
• Email: alsadekmohamed215[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Ulcerative colitis (UC) and Crohns disease (CD) represent the two major forms of inflammatory bowel disease (IBD), characterized by epithelial cell damage and prominent mucosal infiltration by inflammatory cells including granulocytes, macrophages, lymphocytes, and plasma cells.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: November 30, 2022
• Est. primary completion date: November 29, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria: IBD patients diagnosed by endoscopy.

Male and female gender. Disease activity proven clinically and endoscopy . Assiut university hospital patients

Exclusion Criteria:

• Patients who refuse to contribute in this study Pregnancy and breast feeding Cancer patients Renal pathology Diabetes Mellitus Cardiovascular patients Pancreatitis COPD patients

Related Conditions & MeSH terms

• Inflammatory Bowel Diseases
• Intestinal Diseases

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (2)

Nakov R. New markers in ulcerative colitis. Clin Chim Acta. 2019 Oct;497:141-146. doi: 10.1016/j.cca.2019.07.033. Epub 2019 Jul 27. Review. — View Citation

Oikonomou KA, Kapsoritakis AN, Theodoridou C, Karangelis D, Germenis A, Stefanidis I, Potamianos SP. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012 May;47(5):519-30. doi: 10.1007/s00535-011-0516-5. Epub 2011 Dec 27. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	test the sensitivity and specificity of using NGAL in diagnosis of IBD	test the sensitivity and specificity of using NGAL in diagnosis of IBD	One year